Dr. Paul K. Paik

Dr. Paul K. Paik, MD, is a thoracic oncologist specializing in the diagnosis and treatment of lung cancers, including non-small cell and small cell lung carcinoma. He serves as an attending physician in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center and holds an academic appointment as Associate Professor of Medicine at Weill Cornell Medical College. Dr. Paik received his medical degree from NYU Grossman School of Medicine and completed both his residency in internal medicine and fellowship in medical oncology at Memorial Sloan Kettering, where he remains a leader in thoracic oncology.

Dr. Paik’s clinical and research focus centers on the development and application of targeted therapies for molecularly defined subsets of lung cancer. His work has played a key role in advancing the clinical understanding of genetic mutations such as MET exon 14 alterations and other oncogenic drivers in lung tumors. He has served as a principal investigator in numerous phase I–III clinical trials, contributing to the approval and refinement of novel targeted treatments. His scholarly output includes highly cited publications in top-tier journals, covering areas such as resistance mechanisms, biomarker development, and precision oncology strategies in thoracic malignancies.

In addition to his clinical research contributions, Dr. Paik is actively involved in multidisciplinary collaborations and translational initiatives that bridge laboratory findings with real-world applications in cancer therapy. He frequently participates in national and international oncology meetings, where he contributes to consensus guidelines and clinical education in thoracic oncology. Through his leadership in investigational therapeutics, molecular oncology, and academic teaching, Dr. Paik continues to shape the evolving landscape of lung cancer research and targeted treatment development.